RAN, member RAS oncogene familyGenealiases: ARA24 · Gsp1 · TC4
Q-omics provides the consensus-scored RAN profile across patient tissues and cancer cell-line models. RAN expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RAN is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, RAN protein abundance shows 26,589 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where RAN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAN survival associations across molecular data types. RAN RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAN RNA expression–survival associations across cancer types. High RAN expression shows unfavorable associations in HNSC, LIHC, LUAD, ACC, MESO and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RAN RNA expression.
This table summarizes RAN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAN shows higher tumor expression in HNSC, KIRC, COAD, KIRP, BLCA and LIHC. The HNSC box plot shows higher RAN RNA expression in tumor versus normal tissue (log2 FC = +1.011, t-test p < 0.001).
This table shows molecular features associated with RAN in patient tissues and cancer cell lines. In patient samples, RAN shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
